Impax Laboratories Inc. Fundamental Company Report Including Financial, SWOT, Competitors and Industry Analysis

April 2024 | 50 pages | ID: I256A47CEFBBEN
BAC Reports

Abstracts

Impax Laboratories Inc. Fundamental Company Report provides a complete overview of the company’s affairs. All available data is presented in a comprehensive and easily accessed format. The report includes financial and SWOT information, industry analysis, opinions, estimates, plus annual and quarterly forecasts made by stock market experts. The report also enables direct comparison to be made between Impax Laboratories Inc. and its competitors. This provides our Clients with a clear understanding of Impax Laboratories Inc. position in the Pharmaceuticals and Biotechnology Industry.

• The report contains detailed information about Impax Laboratories Inc. that gives an unrivalled in-depth knowledge about internal business-environment of the company: data about the owners, senior executives, locations, subsidiaries, markets, products, and company history.
• Another part of the report is a SWOT-analysis carried out for Impax Laboratories Inc.. It involves specifying the objective of the company's business and identifies the different factors that are favorable and unfavorable to achieving that objective. SWOT-analysis helps to understand company’s strengths, weaknesses, opportunities, and possible threats against it.
• The Impax Laboratories Inc. financial analysis covers the income statement and ratio trend-charts with balance sheets and cash flows presented on an annual and quarterly basis. The report outlines the main financial ratios pertaining to profitability, margin analysis, asset turnover, credit ratios, and company’s long-term solvency. This sort of company's information will assist and strengthen your company’s decision-making processes.
• In the part that describes Impax Laboratories Inc. competitors and the industry in whole, the information about company's financial ratios is compared to those of its competitors and to the industry. The unique analysis of the market and company’s competitors along with detailed information about the internal and external factors affecting the relevant industry will help to manage your business environment. Your company’s business and sales activities will be boosted by gaining an insight into your competitors’ businesses.
• Also the report provides relevant news, an analysis of PR-activity, and stock price movements. The latter are correlated with pertinent news and press releases, and annual and quarterly forecasts are given by a variety of experts and market research firms. Such information creates your awareness about principal trends of Impax Laboratories Inc. business.

About Impax Laboratories Inc.

IMPAX Laboratories, Inc., a specialty pharmaceutical company, engages in the development and commercialization of bioequivalent and brand-name pharmaceuticals, utilizing its controlled-release and other in-house development and formulation expertise. The company is developing products for the treatment of central nervous system (CNS) disorders, which include Alzheimer’s disease, attention deficit hyperactivity disorder, depression, epilepsy, migraines, multiple sclerosis, Parkinson’s disease, and schizophrenia.

Segments

The company operates in two segments, Global Pharmaceuticals Division (Global Division) and the Impax Pharmaceuticals Division (Impax Division).

The Global Division develops, manufactures, sells, and distributes generic pharmaceutical products primarily through four sales channels: the ‘Global product’ sales channel, for generic pharmaceutical prescription products the company sells directly to wholesalers, large retail drug chains, and others; the ‘Private Label’ sales channel, for generic pharmaceutical over-the-counter (OTC) and prescription products the company sells to unrelated third parties who in-turn sell the product under their own label, the ‘Rx Partner’ sales channel, for generic prescription products sold through unrelated third-party pharmaceutical entities pursuant to alliance agreements; and the ‘OTC Partner’ sales channel, for sales of generic pharmaceutical OTC products sold through unrelated third-party pharmaceutical entities pursuant to alliance agreements. The company also provides research and development services under a joint development agreement with another pharmaceutical company.

The Impax Division is engaged in the development of proprietary brand pharmaceutical products through improvements to already approved pharmaceutical products to address CNS disorders. The Impax Division is also engaged in the co-promotion of products developed by unrelated third-party pharmaceutical entities through a direct sales force focused on marketing to physicians (physician detailing sales calls) in the CNS community.

Products

As of February 15, 2010, the company marketed 83 generic pharmaceuticals representing dosage variations of 26 different pharmaceutical compounds through its Global Division and another 16 products representing dosage variations of 4 different pharmaceutical compounds through its alliance agreements’ partners.

In addition, the company has one branded pharmaceutical product for which it has recently completed one Phase III clinical study, a second product for which it is conducting two Phase III clinical trials, and other programs in the early exploratory phase.

Sales and Marketing

The company markets and sells its generic pharmaceutical prescription drug products. The customer base for its products consists primarily of drug wholesalers, warehousing chain drug stores, mass merchandisers, and mail-order pharmacies. The company’s five major customers include Cardinal Health; McKesson Corporation; Amerisource Bergen; Teva; and Walgreens.

Strategic Alliances

The company has entered into a strategic alliance agreement with Teva Pharmaceutical Industries Ltd. The Teva Agreement covers generic versions of the 11 controlled-release generic pharmaceutical branded and OTC products and a 12th product it has have not yet publicly identified.

The company has entered into an alliance agreement with DAVA related to the supply and distribution of 10, 20, 40, and 80 mg strengths of its generic version of the branded OxyContin product.

The company has a license, development, and supply agreement with Putney Inc. under which the parties agreed to collaborate on the development and commercialization of a generic equivalent of the Rimadyl chewable tablets in 25, 75 and/or 100 mg dosage strengths.

The company has a development, license, and supply agreement with Wyeth relating to its generic Claritin-D 12-hour extended release product.

The company has a joint development agreement with Medicis Pharmaceutical Corporation providing for collaboration in the development of five dermatological products, including an advanced form SOLODYN product.

The company has entered into a license and distribution agreement with an affiliate of Shire Laboratories, Inc., under which it received a license to market and sell an authorized generic of Shire’s Adderall XR product. It has entered into a promotional services agreement with Shire Laboratories, Inc. under which it provided physician detail sales calls to promote a Shire branded CNS product.

Suppliers

The company's suppliers include Formosa Laboratories, Ltd. and a division of Ashland, Inc.

Competition

The company’s principal competitors are Sandoz, Inc.; Qualitest Pharmaceuticals; URL Pharma Inc.; Teva Pharmaceutical Industries Ltd.; and Watson Pharmaceuticals, Inc.

History

IMPAX Laboratories, Inc. was founded in 1993.

The above Company Fundamental Report is a half-ready report and contents are subject to change.
It means that we have all necessary data in our database to prepare the report but need 2-3 days to complete it. During this time we are also updating the report with respect to the current moment. So, you can get all the most recent data available for the same price. Please note that preparation of additional types of analyses requires extra time.

Contents

RESEARCH METHODOLOGY

DISCLAIMER

1. IMPAX LABORATORIES INC. COMPANY PROFILE

1.1. Key facts
1.2. Financial Performance
1.3. Key Executives
1.4. Ownership and Major Holders
1.5. Company History

2. IMPAX LABORATORIES INC. BUSINESS OVERVIEW

2.1. Business Description
2.2. Major Products and Services
2.3. Markets and Sales Activities
2.4. Locations, Subsidiaries, Operating Units

3. IMPAX LABORATORIES INC. SWOT ANALYSIS

3.1. Overview
3.2. Strengths
3.3. Weaknesses
3.4. Opportunities
3.5. Threats

4. IMPAX LABORATORIES INC. FINANCIAL ANALYSIS

4.1. Financial Statements
4.1.1. Income Statement
4.1.2. Balance Sheet
4.1.3. Cash Flow
4.2. Financial Ratios
4.2.1. Profitability
4.2.2. Margin Analysis
4.2.3. Asset Turnover
4.2.4. Credit Ratios
4.2.5. Long-Term Solvency
4.2.6. Growth Over Prior Year
4.2.7. Financial Ratios Charts
4.3. Stock Market Snapshot

5. IMPAX LABORATORIES INC. COMPETITORS AND INDUSTRY ANALYSIS

5.1. Impax Laboratories Inc. Direct Competitors
5.2. Comparison of Impax Laboratories Inc. and Direct Competitors Financial Ratios
5.3. Comparison of Impax Laboratories Inc. and Direct Competitors Stock Charts
5.4. Impax Laboratories Inc. Industry Analysis
5.4.1. Pharmaceuticals and Biotechnology Industry Snapshot
  5.4.2. Impax Laboratories Inc. Industry Position Analysis

6. IMPAX LABORATORIES INC. NEWS & EVENTS

6.1. News & PR Activity Analysis
6.2. IR Corporate News
6.3. Marketing News
6.4. Corporate Events

7. IMPAX LABORATORIES INC. EXPERTS REVIEW¹

7.1. Experts Consensus
7.2. Experts Revisions

8. IMPAX LABORATORIES INC. ENHANCED SWOT ANALYSIS²

9. UNITED STATES PESTEL ANALYSIS²

9.1. Political Factors
9.2. Economic Factors
9.3. Social Factors
9.4. Technological Factors
9.5. Environmental Factors
9.6. Legal Factors

10. IMPAX LABORATORIES INC. IFE, EFE, IE MATRICES²

10.1. Internal Factor Evaluation Matrix
10.2. External Factor Evaluation Matrix
10.3. Internal External Matrix

11. IMPAX LABORATORIES INC. PORTER FIVE FORCES ANALYSIS²

12. IMPAX LABORATORIES INC. VRIO ANALYSIS²

APPENDIX: RATIO DEFINITIONS

LIST OF FIGURES

Impax Laboratories Inc. Annual Revenues in Comparison with Cost of Goods Sold and Gross Profit
Profit Margin Chart
Operating Margin Chart
Return on Equity (ROE) Chart
Return on Assets (ROA) Chart
Debt to Equity Chart
Current Ratio Chart
Impax Laboratories Inc. 1-year Stock Charts
Impax Laboratories Inc. 5-year Stock Charts
Impax Laboratories Inc. vs. Main Indexes 1-year Stock Chart
Impax Laboratories Inc. vs. Direct Competitors 1-year Stock Charts
Impax Laboratories Inc. Article Density Chart

1 – Data availability depends on company’s security policy.
2 – These sections are available only when you purchase a report with appropriate additional types of analyses.
The complete financial data is available for publicly traded companies.

List Of Tables

LIST OF TABLES

Impax Laboratories Inc. Key Facts
Profitability
Management Effectiveness
Income Statement Key Figures
Balance Sheet Key Figures
Cash Flow Statement Key Figures
Financial Performance Abbreviation Guide
Impax Laboratories Inc. Key Executives
Impax Laboratories Inc. Major Shareholders
Impax Laboratories Inc. History
Impax Laboratories Inc. Products
Revenues by Segment
Revenues by Region
Impax Laboratories Inc. Offices and Representations
Impax Laboratories Inc. SWOT Analysis
Yearly Income Statement Including Trends
Income Statement Latest 4 Quarters Including Trends
Yearly Balance Sheet Including Trends
Balance Sheet Latest 4 Quarters Including Trends
Yearly Cash Flow Including Trends
Cash Flow Latest 4 Quarters Including Trends
Impax Laboratories Inc. Profitability Ratios
Margin Analysis Ratios
Asset Turnover Ratios
Credit Ratios
Long-Term Solvency Ratios
Financial Ratios Growth Over Prior Year
Impax Laboratories Inc. Capital Market Snapshot
Impax Laboratories Inc. Direct Competitors Key Facts
Direct Competitors Profitability Ratios
Direct Competitors Margin Analysis Ratios
Direct Competitors Asset Turnover Ratios
Direct Competitors Credit Ratios
Direct Competitors Long-Term Solvency Ratios
Pharmaceuticals and Biotechnology Industry Statistics
Impax Laboratories Inc. Industry Position
Company vs. Industry Income Statement Analysis
Company vs. Industry Balance Sheet Analysis
Company vs. Industry Cash Flow Analysis
Company vs. Industry Ratios Comparison
Impax Laboratories Inc. Consensus Recommendations¹
Analyst Recommendation Summary¹
Price Target Summary¹
Experts Recommendation Trends¹
Revenue Estimates Analysis¹
Earnings Estimates Analysis¹
Historical Surprises¹
Revenue Estimates Trend¹
Earnings Estimates Trend¹
Revenue Revisions¹

ANALYSIS FEATURES

SWOT Analysis

SWOT, which stands for Strengths, Weaknesses, Opportunities and Threats, is an analytical framework that identifies the internal and external factors that are favorable and unfavorable for a company.

Enhanced SWOT Analysis

Enhanced SWOT is a 3×3 grid that arranges strengths, weaknesses, opportunities and threats into one scheme:

• How to use the strengths to take advantage of the opportunities?
• How to use the strengths to reduce likelihood and impact of the threats?
• How to overcome the weaknesses that obstruct taking advantage of the opportunities?
• How to overcome the weaknesses that can make the threats a reality?

Upon answering these questions a company can develop a project plan to improve its business performance.

PESTEL Analysis

PESTEL (also termed as PESTLE) is an ideal tool to strategically analyze what influence different outside factors – political, economic, sociocultural, technological, environmental and legal – exert on a business to later chart its long term targets.

Being part of the external analysis when carrying out a strategic assessment or performing a market study, PESTEL gives an overview of diverse macro-environmental factors that any company should thoughtfully consider. By perceiving these outside environments, businesses can maximally benefit from the opportunities while minimizing the threats to the organization.

Key Factors Examined by PESTEL Analysis:

• Political – What opportunities and pressures are brought by political bodies and what is the degree of public regulations’ impact on the business?
• Economic – What economic policies, trends and structures are expected to affect the organization, what is this influence’s degree?
• Sociological – What cultural and societal aspects will work upon the demand for the business’s products and operations?
• Technological – What impact do the technological aspects, innovations, incentives and barriers have on the organization?
• Environmental – What environmental and ecological facets, both locally and farther afield, are likely to predetermine the business?
• Legal – What laws and legislation will exert influence on the style the business is carried out?

IFE, EFE, IE Matrices

The Internal Factor Evaluation matrix (IFE matrix) is a strategic management tool helping audit or evaluate major weaknesses and strengths in a business’s functional areas. In addition, IFE matrix serves as a basis for identifying and assessing relationships amongst those areas. The IFE matrix is utilised in strategy formulation.

The External Factor Evaluation matrix (EFE matrix) is a tool of strategic management that is typically utilised to assess current market conditions. It is an ideal instrument for visualising and prioritising the threats and opportunities a firm is facing.

The essential difference between the above mentioned matrices lies in the type of factors incorporated in the model; whilst the latter is engaged in internal factors, the former deals exceptionally with external factors – those exposed to social, political, economic, legal, etc. external forces.

Being a continuation of the EFE matrix and IFE matrix models, the Internal External matrix (IE matrix) rests upon an investigation of external and internal business factors integrated into one suggestive model.

Porter Five Forces Analysis

The Porter’s five forces analysis studies the industry of operation and helps the company find new sources of competitive advantage. The analysis surveys an industry through five major questions:

1. What composes a threat of substitute products and services?
2. Is there a threat of new competitors entering the market?
3. What is the intensity of competitive rivalry?
4. How big is the bargaining power of buyers?
5. How significant is the bargaining power of suppliers?

VRIO Analysis

VRIO stands for Value, Rarity, Imitability, Organization. This analysis helps to evaluate all company’s resources and capabilities and bring them together into one aggregate table that includes:

• Tangible resources
  • Financial
  • Physical
  • Technological
  • Organizational
• Intangible resources
  • Human
  • Innovation and Creativity
  • Reputation
• Organizational capabilities

The result of the analysis gives a clear picture of company’s competitive and economic implications, answering the questions if the resources mentioned above are:

• Valuable?
• Rare?
• Costly to imitate?
• Organized properly?